TSN
42
4
ED
46
3
DOW
35
-5
KSS
39
-4
TEL
71
3
PG
48
7
XRAY
29
3
TXT
66
-3
LRCX
52
2
NWS
83
4
ABT
62
5
FCX
63
-4
XRX
37
2
AAP
30
-3
SPG
63
7
VTR
50
3
WMB
71
3
MO
57
3
WM
82
3
DG
10
2
TSN
42
4
ED
46
3
DOW
35
-5
KSS
39
-4
TEL
71
3
PG
48
7
XRAY
29
3
TXT
66
-3
LRCX
52
2
NWS
83
4
ABT
62
5
FCX
63
-4
XRX
37
2
AAP
30
-3
SPG
63
7
VTR
50
3
WMB
71
3
MO
57
3
WM
82
3
DG
10
2
Financhill
Back

Apellis Pharmaceuticals 10K Form

Buy
51

APLS
Apellis Pharmaceuticals

Last Price:
29.96
Seasonality Move:
22.1%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive APLS News And Ratings

See the #1 stock for the next 7 days that we like better than APLS

APLS Financial Statistics

Sales & Book Value

Annual Sales: $396.59M
Cash Flow: $34.1M
Price / Cash Flow: 0
Annual Sales: $1.94
Price / Book: 15.75

Profitability

EPS (TTM): -2.03000
Net Income (TTM): $-250.1M
Gross Margin: $338.08M
Return on Equity: -104.65%
Return on Assets: -29.46%

Apellis Pharmaceuticals Earnings Forecast

Key Apellis Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 6 years for APLS is 85.25%.
  • The Selling, General & Administrative Expenses for APLS have been equal to 126.28% of Gross Profit Margin.
  • The Research & Development expenses have been 89.36% of Revenue.
  • The Interest Expense is -5.60% of Operating Income.
  • The Net Earning history of APLS is -133.29% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Apellis Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: APLS
CUSIP: 03753U
Website: apellis.com

Debt

Debt-to-Equity Ratio: 1.91
Current Ratio: 4.36
Quick Ratio: 3.56

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

APLS Technical Analysis vs Fundamental Analysis

Buy
51
Apellis Pharmaceuticals (APLS) is a Buy

Is Apellis Pharmaceuticals a Buy or a Sell?